单中心前后对比:异基因造血细胞移植受者皮下免疫球蛋白替代治疗
该单中心回顾性前后对比纳入2011—2019年接受异基因造血细胞移植的209例患者,按本院2017年4月引入皮下免疫球蛋白替代治疗分为Pre-ScIgRT组118例与Post-ScIgRT组91例。Post-ScIgRT组2年总生存率81% vs Pre-ScIgRT组65%(p=0.02),2年非复发死亡累积发生率7% vs 18%(p=0.02),感染累积发生率21% vs 38%(p=0.01)。作者认为皮下免疫球蛋白替代治疗可能降低移植后感染率并改善预后。
要点
- Post-ScIgRT组2年总生存率81%,Pre-ScIgRT组65%(p=0.02)。
- 2年非复发死亡累积发生率Post-ScIgRT组7%,Pre-ScIgRT组18%(p=0.02)。
- 观察期感染累积发生率Post-ScIgRT组21%,Pre-ScIgRT组38%(p=0.01)。
核心结论
- 本研究提示皮下免疫球蛋白替代治疗可能降低异基因造血细胞移植后感染率并改善预后。
研究设计与样本
- 单中心回顾性前后对比分析,纳入2011年至2019年在本院接受异基因造血细胞移植的209例患者。
- 本院自2017年4月起可提供皮下免疫球蛋白替代治疗,2011年1月至2017年3月治疗者为Pre-ScIgRT组(n=118),2017年4月至2019年12月治疗者为Post-ScIgRT组(n=91)。
主要发现
- 2年总生存率Post-ScIgRT组81% vs Pre-ScIgRT组65%(p=0.02)。
- 2年非复发死亡累积发生率Post-ScIgRT组7% vs Pre-ScIgRT组18%(p=0.02)。
- Pre-ScIgRT组44例患者发生78次感染事件,Post-ScIgRT组19例患者发生28次感染事件。
- 观察期记录感染累积发生率Post-ScIgRT组21% vs Pre-ScIgRT组38%(p=0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunoglobulin replacement therapy (IgRT) reduces the risk of infection in hypogammaglobulinaemia secondary to chronic lymphocytic leukaemia and multiple myeloma. However, the benefit of IgRT, especially subcutaneous IgRT (ScIgRT), has not been assessed in hypogammaglobulinaemia after allogeneic haematopoietic cell transplantation (allo-HCT). We performed a pre-post comparison of the clinical impact of ScIgRT after allo-HCT in a retrospective analysis of 209 patients who underwent allogeneic HCT at our institution from 2011 to 2019. Since ScIgRT became available at our institution in April 2017, we categorized patients treated from January 2011 to March 2017 as the Pre-ScIgRT group (n = 118) and those treated from April 2017 to December 2019 as the Post-ScIgRT group (n = 91). The 2-year overall survival rate was 65% in the Pre-ScIgRT group and 81% in the Post-ScIgRT group (p = 0.02). The cumulative incidence (CI) of non-relapse mortality at 2 years was 18% and 7% (p = 0.02). There were 78 infectious events in 44 patients in the Pre-ScIgRT group and 28 such events in 19 patients in the Post-ScIgRT group. The CI of the documented infection during the observation period was between 38% and 21% (p = 0.01). Our study suggests that ScIgRT may reduce infection rates and improve prognosis after allo-HCT.
引用
- Suga M, Fuji S, Tada Y, et al. A single-institution pre-post comparison of subcutaneous immunoglobulin replacement therapy in allogeneic haematopoietic cell transplantation recipients. Br J Haematol. 2023. PMID: 37963427. doi:10.1111/bjh.19203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。